Advertisement
ALNY vs BCRX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a Hold and BCRX is a Hold.
ALNY in downward trend: price dove below 50-day moving average on October 01, 2026
ALNY moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend. In 28 of 39 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 72%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALNY as a result. In 56 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.
The Moving Average Convergence Divergence Histogram (MACD) for ALNY turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 31 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.
The 10-day moving average for ALNY crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 68%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
The Aroon Indicator for ALNY entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALNY's RSI Indicator exited the oversold zone, 20 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +3.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALNY advanced for three days, in 219 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
ALNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. ALNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (25.253) is normal, around the industry mean (26.782). P/E Ratio (44.488) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.330) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (6.911) is also within normal values, averaging (437.542).
The Tickeron Profit vs. Risk Rating rating for this company is 90 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
BCRX in downward trend: price dove below 50-day moving average on September 08, 2026
BCRX moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend. In 42 of 49 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BCRX as a result. In 78 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The 10-day moving average for BCRX crossed bearishly below the 50-day moving average on September 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for BCRX entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BCRX's RSI Oscillator exited the oversold zone, 31 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 67 cases where BCRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for BCRX just turned positive on October 07, 2026. Looking at past instances where BCRX's MACD turned positive, the stock continued to rise in 45 of 54 cases over the following month. The odds of a continued upward trend are 83%.
Following a +1.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCRX advanced for three days, in 204 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
BCRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-25.695) is normal, around the industry mean (43.873). P/E Ratio (7.463) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.097) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating fairly steady price growth. BCRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
ALNY | BCRX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 75 | 70 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 86 Overvalued | 16 Undervalued | |
PROFIT vs RISK RATING 1..100 | 90 | 100 | |
SMR RATING 1..100 | 14 | 100 | |
PRICE GROWTH RATING 1..100 | 80 | 57 | |
P/E GROWTH RATING 1..100 | 100 | 32 | |
SEASONALITY SCORE 1..100 | 50 | 1 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BCRX's Valuation (16) in the Biotechnology industry is significantly better than the same rating for ALNY (86). This means that BCRX’s stock grew significantly faster than ALNY’s over the last 12 months.
ALNY's Profit vs Risk Rating (90) in the Biotechnology industry is in the same range as BCRX (100). This means that ALNY’s stock grew similarly to BCRX’s over the last 12 months.
ALNY's SMR Rating (14) in the Biotechnology industry is significantly better than the same rating for BCRX (100). This means that ALNY’s stock grew significantly faster than BCRX’s over the last 12 months.
BCRX's Price Growth Rating (57) in the Biotechnology industry is in the same range as ALNY (80). This means that BCRX’s stock grew similarly to ALNY’s over the last 12 months.
BCRX's P/E Growth Rating (32) in the Biotechnology industry is significantly better than the same rating for ALNY (100). This means that BCRX’s stock grew significantly faster than ALNY’s over the last 12 months.
| ALNY | BCRX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 77% | 2 days ago 84% |
| Stochastic ODDS (%) | 2 days ago 76% | 2 days ago 78% |
| Momentum ODDS (%) | 2 days ago 69% | 2 days ago 81% |
| MACD ODDS (%) | 2 days ago 67% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 66% | 2 days ago 75% |
| TrendMonth ODDS (%) | 2 days ago 70% | 2 days ago 80% |
| Advances ODDS (%) | 6 days ago 73% | 23 days ago 77% |
| Declines ODDS (%) | 2 days ago 68% | 2 days ago 79% |
| BollingerBands ODDS (%) | 2 days ago 56% | 7 days ago 78% |
| Aroon ODDS (%) | 2 days ago 68% | 2 days ago 81% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 1 FA rating(s) are green while BCRX’s FA Score has 2 green FA rating(s).
- ALNY’s FA Score: 1 green, 4 red.
- BCRX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 4 TA indicator(s) are bullish while BCRX’s TA Score has 5 bullish TA indicator(s).
- ALNY’s TA Score: 4 bullish, 6 bearish.
- BCRX’s TA Score: 5 bullish, 5 bearish.
Price Growth
ALNY (@Biotechnology) experienced а -0.05% price change this week, while BCRX (@Pharmaceuticals: Generic) price change was +1.51% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.26%. For the same industry, the average monthly price growth was -18.80%, and the average quarterly price growth was -19.69%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -5.81%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was +11.19%.
Reported Earning Dates
ALNY is expected to report earnings on Oct 29, 2026.
BCRX is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (-8.26% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (-5.81% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
ALNY and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALNY has been loosely correlated with PHAT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ALNY jumps, then PHAT could also see price increases.
| Ticker / NAME | Correlation To ALNY | 1D Price Change % | ||
|---|---|---|---|---|
| ALNY | 100% | -1.41% | ||
| PHAT - ALNY | 45% Loosely correlated | -1.82% | ||
| UTHR - ALNY | 35% Loosely correlated | -1.22% | ||
| AXON - ALNY | 35% Loosely correlated | -0.26% | ||
| MDGL - ALNY | 34% Loosely correlated | -3.22% | ||
| BCRX - ALNY | 33% Loosely correlated | -3.47% | ||
More | ||||
BCRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To BCRX | 1D Price Change % | ||
|---|---|---|---|---|
| BCRX | 100% | -3.47% | ||
| VCYT - BCRX | 46% Loosely correlated | -2.07% | ||
| HOWL - BCRX | 39% Loosely correlated | +0.95% | ||
| ROIV - BCRX | 38% Loosely correlated | -3.58% | ||
| BEAM - BCRX | 38% Loosely correlated | -2.79% | ||
| CLDX - BCRX | 37% Loosely correlated | -4.01% | ||
More | ||||